1. Home
  2. ICCM vs BOLT Comparison

ICCM vs BOLT Comparison

Compare ICCM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$2.21

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
BOLT
Founded
2006
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.1M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ICCM
BOLT
Price
$2.21
$3.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.50
$34.00
AVG Volume (30 Days)
89.0K
23.6K
Earning Date
05-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
$139.51
N/A
Revenue Next Year
$75.66
$133.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$0.13
$3.13
52 Week High
$9.54
$7.20

Technical Indicators

Market Signals
Indicator
ICCM
BOLT
Relative Strength Index (RSI) 33.57 51.18
Support Level $2.15 $3.14
Resistance Level $3.59 $4.33
Average True Range (ATR) 0.16 0.27
MACD 0.01 0.04
Stochastic Oscillator 10.45 63.39

Price Performance

Historical Comparison
ICCM
BOLT

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: